Problems in the treatment of rheumatoid arthritis and prospects for the use of an IL-1 inhibitor (Anakinra). (Resolution of the Expert Council, May 19, 2022)

1. Cvetkovic RS, Keating G. Anakinra. BioDrugs. 2002;16(4): 303–311; discussion 313–314. doi: 10.2165/00063030- 200216040-00005

2. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196–204. doi: 10.1002/1529-0131

3. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(3): 614–624. doi: 10.1002/art.10141

4. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, et al.; 990145 Study Group. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63(9):1062–1068. doi: 10.1136/ard.2003.016014.

5. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48(4):927–934. doi: 10.1002/art.10870

6. Nuki G, Bresnihan B, Bear MB, McCabe D; European Group Of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(11):2838–2846. doi: 10.1002/art.10578

7. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, et al.; 990145 Study Group. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63(9): 1062–1068. doi: 10.1136/ard.2003.016014

8. Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al. The safety of anakinra in high-risk patients with acti ve rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum. 2004;50(6):1752–1760. doi: 10.1002/art.20277

9. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(8):1006–1012. doi: 10.1136/ard.2005.048371

10. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118–11125. doi: 10.3899/ jrheum.090074

11. Bedaiwi MK, Almaghlouth I, Omair MA. Effectiveness and adverse effects of anakinra in treatment of rheumatoid arthritis: a systematic review. Eur Rev Med Pharmacol Sci. 2021;25(24):7833–7839. doi: 10.26355/eurrev_202112_27630

12. Nam JL, Ramino S, Gaujoux-Viala C, et al. Extended report: Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–528. doi: 10.1136/annrheumdis2013-204577

13. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Protocol). Cochrane Database of Systematic Reviews. 2009;2:CD007848. doi: 10.1002/14651858.CD007848

14. Nikfar S, Saiyarsarai P, Tigabu BM, Abdollahi M. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int. 2018;38(8):1363–1383. doi: 10.1007/s00296-018-4041-1

15. Nasonov EL, Samsonov MYu. The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist). Rheumatology Science and Practice. 2022;60(3):280–298 (In Russ.). doi: 10.47360/1995-4484- 2022-280-298

16. Doria A, Zen M, Bettio S, Gatto M, Bassi N, et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev. 2012;12(1):22–30. doi: 10.1016/j.autrev.2012.07.018

17. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38. doi: 10.1016/S0140-6736(16)30173-8

18. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al.; T2T Expert Committee. Treating rheumatoid ar thritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637. doi: 10.1136/ard.2009.123919

19. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi: 10.1136/annrheumdis-2019-216655

20. Nasonov EL, Olyunin YuA, Lila AM. RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE. Rheumatology Science and Practice. 2018;56(3):263–271 (In Russ.) doi: 10.14412/1995-4484-2018-263-271

21. Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–35. doi: 10.1136/annrheumdis-2020-217344

22. Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, et al. EULAR points to consider for the management of difficultto-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20–33. doi: 10.1136/annrheumdis-2021-220973

23. Tan Y, Buch MH. ‘Difficult to treat’ rheumatoid arthritis: current position and considerations for next steps. RMD Open. 2022;8(2):e002387. doi: 10.1136/rmdopen-2022-002387

24. McGonagle D, Watad A, Savic S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmun Rev. 2018;17(11):1115–1123. doi: 10.1016/j.autrev.2018.06.001

25. Atzeni F, Rodríguez-Carrio J, Popa CD, Nurmohamed MT, Szűcs G, Szekanecz Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(5):270–290. doi: 10.1038/s41584-021-00593-3

26. Tian Z, Mclaughlin J, Verma A, Chinoy H, Heald AH. The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Endocrinol Metab. 2021;10(2):125–131. doi: 10.1097/XCE.0000000000000244

27. Baker JF, England BR, George M. Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis, Ann Rheum Dis. 2021;72:annrheumdis-2020-2019140.

28. Ruscitti P, Masedu F, Alvaro S, Airò P, Battafarano N, et al. Antiinterleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med. 2019;16(9):e1002901. doi: 10.1371/journal.pmed.1002901

29. Ruscitti P, Berardicurti O, Cipriani P, Giacomelli R; TRACK study group. Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. Clin Exp Rheumatol. 2021;39(2):403–406.

30. Ruscitti P, Ursini F, Cipriani P, Greco M, Alvaro S, et al. IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study. Medicine (Baltimore). 2019;98(7):e14587. doi: 10.1097/MD.0000000000014587

31. Khalid Y, Dasu N, Shah A, Brown K, Kaell A, et al. Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis. ESC Heart Fail. 2020;7(6): 3745–3753. doi: 10.1002/ehf2.12947

32. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117(20):2662–2669. doi: 10.1161/CIRCULATIONAHA.107.731877

33. Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7(4):619–628. doi: 10.1161/CIRCIMAGING.113.001193

34. Almeida-Santiago, C., Quevedo-Abeledo, J.C., HernándezHernández, V. et al. Interleukin 1 receptor antagonist relation to cardiovascular disease risk in patients with rheumatoid arthritis. Sci Rep 12, 13698 (2022). doi: 10.1038/s41598-022-18128-5

35. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156(2):336–341. doi: 10.1016/j.ahj.2008.02.025

36. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123. doi: 10.1002/art.41752

37. Kontzias A, Barkhodari A, Yao Q. Pericarditis in Systemic Rheumatologic Diseases. Curr Cardiol Rep. 2020;22(11):142. doi: 10.1007/s11886-020-01415-w

38. Correia ETO, Dos Santos Barbetta LM, de Almeida JPCL, Mesquita ET. Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety. J Cardiovasc Pharmacol. 2020;76(1):42–49. doi: 10.1097/FJC.0000000000000839